Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Adverse Reactions to Biologics

Editor(s): Puig L. (Barcelona) 
Gulliver W. (St. John's, NL) 

Status: available   
Publication year: 2018
Buy this book
Digital Version: CHF 139.00, EUR 130.00, USD 164.00
Print Version: CHF 139.00, EUR 130.00, USD 164.00
The final prices may differ from the prices shown due to specifics of VAT rules, postage and handling.
Order this title

You already have online access to this title. If you would like to buy a personal digital or print copy, please click here.

This book belongs to
Current Problems in Dermatology , Vol. 53
Editor(s): Itin P. (Basel) 
Jemec G.B.E. (Roskilde) 
X + 108 p., 25 fig., 24 in color, 12 tab., hard cover, 2018
Status: available   
ISSN: 1421-5721
e-ISSN: 1662-2944

An essential reference source
In many areas of medicine physicians still face the great challenge of finding therapies that will meet the patients’ needs. In dermatology the challenge has arisen on multiple fronts through advances in the understanding of the immunopathogenesis of many inflammatory and malignant cutaneous disorders. Breakthroughs, combined with significant developments in targeted immunotherapy, have resulted in improved outcomes as these newer therapies are being used for both approved indications and as off-label therapies for various chronic inflammatory skin disorders and many forms of skin cancer.

In the expectation that by truly understanding the safety profile of these targeted therapies patients’ outcomes will be significantly improved, this book offers insights into topics such as adverse reactions, infectious complications and the perioperative use of biologics in psoriasis, immunogenicity of biologic therapies, paradoxical reactions, safety of biologics used to treat autoimmune bullous diseases and primary cutaneous lymphomas, adverse reactions and skin manifestations of therapies targeting melanoma and non-melanoma skin cancer and other neoplastic diseases.

Eminent researchers with extensive clinical experience have contributed to this publication, providing an in-depth overview of the latest knowledge in this field.